Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04471038 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
A Phase 1 study of Influenza and Influenza Type B, sponsored by SAb Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT04471038: Completed Phase 1 study of Influenza and Influenza Type B, sponsored by SAb Biotherapeutics.
NCT04471038 is a Phase 1 study of Influenza and Influenza Type B that has completed, run by SAb Biotherapeutics. The registered enrollment target is 27 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04471038, a Phase 1 study of Influenza and Influenza Type B, has completed, sponsored by SAb Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
Influenza causes substantial morbidity and mortality worldwide despite available antivirals and vaccines. SAB Biotherapeutics, Inc. has developed SAB-176, an anti-influenza human immunoglobulin (transchromosomic \[Tc\] bovine-derived) intravenous therapeutic to treat past and current strains of Type A Influenza and Type B Influenza. This study will evaluate the safety, tolerability, and pharmacokinetics of SAB-176 in healthy participants.
Primary Outcome
Incidence and severity of other adverse events and severe adverse events (SAE)
Conditions Studied
Interventions
- OTHER Normal Saline
- BIOLOGICAL SAB-176
Study Locations (1)
Texas
- PPD, Phase 1 Clinic - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2021-04-19 |
| Phase | Phase 1 |
What the finished NCT04471038 record still lists
NCT04471038 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT04471038 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04471038 about?
NCT04471038 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants". Influenza causes substantial morbidity and mortality worldwide despite available antivirals and vaccines. SAB Biotherapeutics, Inc. has developed SAB-176, an anti-influenza human immunoglobulin (transchromosomic \[Tc\] bovine-derived) intravenous therapeutic to treat past and current strains of Type...
What is the current status of trial NCT04471038?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2020-07-29. Estimated completion is 2021-04-19.
What conditions does trial NCT04471038 study?
This clinical trial studies the following conditions: Influenza, Influenza Type B, Influenza Type A.
What interventions are being tested in trial NCT04471038?
The interventions under investigation include: Normal Saline (OTHER), SAB-176 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04471038?
This trial is sponsored by SAb Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04471038 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04471038's enrollment target sits among peer trials
27 144th of 156 higher than 12 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI